BioSig Technologies prices 6.996M shares at 35.73c in registered direct offering

BioSig Technologies has entered into a definitive agreement for the issuance and sale of an aggregate of 6,996,922 shares of its common stock, Series A warrants to purchase up to 6,996,922 shares of common stock and Series B warrants to purchase up to 6,996,922 shares of common stock, at a purchase price of $0.3573 per share of common stock and associated warrants, in a registered direct offering priced at-the-market under Nasdaq rules. H.C. Wainwright & Co. is acting as exclusive placement agent for the offering. The warrants will have an exercise price of $0.3573 per share, will become exercisable on the effective date of stockholder approval for the issuance of the shares upon exercise of the warrants. The Series A warrants will expire five years from the date of issuance and the Series B warrants will expire eighteen months from the date of issuance. The closing of the offering is expected to occur on or about November 13, 2023, subject to the satisfaction of customary closing conditions. The gross proceeds from the offering are expected to be approximately $2.5 million. BioSig intends to use the net proceeds of this offering for working capital and general corporate purposes.